FRI0066 Behavior of the multi-biomarker disease activity (vectra da algorithm) score and components in patients with rheumatoid arthritis treated with tocilizumab

Hanami, Kentaro; Hirata, Shintaro; Tasaka, H; Li, W.; Bolce, Rebecca; Sasso, Eric H.; Defranoux, Nadine; Yamaoka, Kunihiro; Saito, Kazuyoshi; Tanaka, Yoshiya

doi:10.1136/annrheumdis-2013-eular.1193

Cited by 2 publications

(2 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our findings suggest that the substantial increases in IL-6 concentrations partially countered the decreases in CRP, SAA, and other biomarkers, thereby contributing to the proportionately smaller improvements observed in the MBDA score, compared with DAS28-CRP and CDAI. This finding is consistent with that of a previous study in Japanese patients with established RA, in which 24 and 52 weeks of TCZ treatment led to increased IL-6 concentrations in the majority of patients, and to smaller median percentage decreases in MBDA score compared with DAS28-ESR and CDAI [ 25 ].…”

Section: Discussionsupporting

confidence: 92%

Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis

Reiss¹,

Devenport²,

Low³

et al. 2015

Rheumatol Int

View full text Add to dashboard Cite

The multi-biomarker disease activity (MBDA) score measures 12 proteins involved in the pathophysiology of rheumatoid arthritis (RA) to assess disease activity (DA). Previous studies demonstrated correlations between MBDA and clinical DA scores with some RA therapies. In this analysis, the relationship between DA and MBDA scores and changes in MBDA component biomarkers were evaluated in tocilizumab (TCZ)-treated patients. Patients from the ACT-RAY study were included in this analysis if they had DA measures and serum collected at pre-specified time points with sufficient serum for MBDA testing at ≥1 visit. Descriptive statistics, associations between outcomes, and percentage agreement between DA categories were calculated. Seventy-eight patients were included and were similar to the ACT-RAY population. Correlations between MBDA score and DAS28-CRP were ρ = 0.50 at baseline and ρ = 0.26 at week 24. Agreement between low/moderate/high categories of MBDA score and DAS28-CRP was observed for 77.1 % of patients at baseline and 23.7 % at week 24. Mean changes from baseline to weeks 4, 12, and 24 were proportionately smaller for MBDA score than DAS28-CRP. Unlike some other MBDA biomarkers, interleukin-6 (IL-6) concentrations increased in most patients during TCZ treatment. Correlations and agreement between MBDA and DAS28-CRP or CDAI scores were lower at week 24 versus baseline. The proportionately smaller magnitude of response observed for MBDA score versus DAS28-CRP may be due to the influence of the increase in IL-6 concentrations on MBDA score. Thus, MBDA scores obtained during TCZ treatment should be interpreted cautiously and in the context of available clinical information.

show abstract

Section: Discussionsupporting

confidence: 92%

Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis

Reiss¹,

Devenport²,

Low³

et al. 2015

Rheumatol Int

View full text Add to dashboard Cite

show abstract

“…Годовой анализ динамики значений MBDA при терапии РА ингибиторами ФНОα (адалимумаб, этанерцепт, инфликсимаб) показал возможность его использования для предсказания развития синовита (на 26-й неделе терапии) и рентгенологических признаков суставной деструкции (на 24-й неделе) [79,80]. При терапии ингибитором рецептора ИЛ6 тоцилизумабом отмечено снижение содержания всех биомаркеров, входящих в индекс, при этом его значения достоверно коррелировали с результатами определения DAS28-СОЭ (p=0,54), CDAI (p=0,31), SDAI (p=0,54) до начала и DAS28-СОЭ (r=0,47) CDAI (r=0,37) на 52-й неделе терапии [81]. Сходные данные о взаимосвязи значений MBDA и вышеперечисленных клинических индексов активности РА получены и на фоне применения ингибитора Янус-киназы (JAK) тофацитиниба (табл.…”

unclassified

Elaboration and Application of the Diagnostic Index Based on Multivariate Analysis of Biomarkers to Determine the Activity of Rheumatoid Arthritis

Новиков¹,

Александрова²,

Насонов³

2014

rsp

View full text Add to dashboard Cite

П р о г р е с с в р е в м а т о л о г и и в X X I в е к е Е.Н. Александрова-заведующая лабораторией иммунологии и молекулярной биологии ревматических заболеваний ФГБУ «НИИР им. В.А. Насоновой» РАМН, доктор мед. наук Е.Л. Насонов-директор ФГБУ «НИИР им. В.А. Насоновой» РАМН, академик РАН, доктор мед. наук, профессор А.А. Новиков-ведущий научный сотрудник лаборатории иммунологии и молекулярной биологии ревматических заболеваний ФГБУ «НИИР им. В.А. Насоновой» РАМН, канд. биол. наук ФГБУ «Научноисследовательский институт ревматологии им. В.А. Насоновой» РАМН,

show abstract

FRI0066 Behavior of the multi-biomarker disease activity (vectra da algorithm) score and components in patients with rheumatoid arthritis treated with tocilizumab

Cited by 2 publications

References 47 publications

Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis

Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis

Elaboration and Application of the Diagnostic Index Based on Multivariate Analysis of Biomarkers to Determine the Activity of Rheumatoid Arthritis

Contact Info

Product

Resources

About